Evidence map›Paper›PMID 41482387›Full record

ArticleIn vivo (Athens, Greece)

Evaluating the Reproductive Impact of Pembrolizumab in Mice: Ovarian Function and Hormonal Changes.

Bengü Mutlu Sütcüoğlu, Osman Sütcüoğlu, Betül Öğüt, Orhun Akdoğan, Çağnur Elpen Kodaz, Canan Yilmaz, Özlem Erdem, Elvan Anadol, Nuriye Özdemir

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bengü Mutlu SütcüoğluDepartment of Obstetrics and Gynaecology, Ankara Atatürk Sanatoryum Research and Training Hospital, Ankara, Türkiye; bengu.sutcuoglu@saglik.gov.tr.
Osman SütcüoğluDepartment of Medical Oncology, Gazi University, Ankara, Türkiye.
Betül ÖğütDepartment of Pathology, Gazi University, Ankara, Türkiye.
Orhun AkdoğanDepartment of Medical Oncology, Gazi University, Ankara, Türkiye.
Çağnur Elpen KodazDepartment of Family Medicine, Bilecik Şeyh Edabali University, Bilecik, Türkiye.
Canan YilmazDepartment of Biochemistry, Gazi University, Ankara, Türkiye.
Özlem ErdemDepartment of Pathology, Gazi University, Ankara, Türkiye.
Elvan AnadolLaboratory Animal Breeding and Experimental Research Center, Gazi University, Ankara, Türkiye.
Nuriye ÖzdemirDepartment of Medical Oncology, Gazi University, Ankara, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimPembrolizumab, an immune checkpoint inhibitor used in cancer therapy, is associated with immune-related adverse effects, yet its impact on female reproductive health remains unclear. This study aimed to evaluate the effects of pembrolizumab on ovarian function and hormonal balance in a mouse model. MATERIALS AND

methodsTwenty-four Swiss albino mice were divided into acute and chronic groups, each comprising a pembrolizumab-treated and a saline-control subgroup (n=6 per subgroup). All mice underwent a superovulation protocol, and serum levels of estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and anti-Müllerian hormone (AMH) were measured using enzyme-linked immunosorbent assay kits. Ovarian tissues were evaluated histologically for follicular counts, including primordial, preantral, and secondary follicles.

resultsEstradiol levels were significantly reduced in pembrolizumab-treated mice compared with controls (

conclusionPembrolizumab administration in mice led to reduced estradiol levels and diminished primordial follicle counts, indicating potential adverse effects on ovarian reserve. These findings highlight the importance of evaluating reproductive risks in female patients receiving immunotherapy.

Indexed as

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsOvaryReproductionAnimalsAnti-Mullerian HormoneEstradiolFemaleFollicle Stimulating HormoneLuteinizing HormoneMiceOvarian FollicleAntibodies, Monoclonal, HumanizedAnti-Mullerian HormoneEstradiolFollicle Stimulating HormoneImmune Checkpoint InhibitorsLuteinizing Hormonepembrolizumabestradiolfemale fertilityimmune checkpoint inhibitorsovarian reservePembrolizumabpreclinical studyreproductive toxicity

Identifiers

PMID41482387
PMCPMC12764203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.